Literature DB >> 16410248

Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.

Conrad Yap Edosada1, Clifford Quan, Christian Wiesmann, Thuy Tran, Dan Sutherlin, Mark Reynolds, J Michael Elliott, Helga Raab, Wayne Fairbrother, Beni B Wolf.   

Abstract

Fibroblast activation protein (FAP) is a transmembrane serine peptidase that belongs to the prolyl peptidase family. FAP has been implicated in cancer; however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed. To identify peptide motifs for FAP-selective inhibitor design, we used P(2)-Pro(1) and acetyl (Ac)-P(2)-Pro(1) dipeptide substrate libraries, where P(2) was varied and substrate hydrolysis occurs between Pro(1) and a fluorescent leaving group. With the P(2)-Pro(1) library, FAP preferred Ile, Pro, or Arg at the P(2) residue; however, DPP-4 showed broad reactivity against this library, precluding selectivity. By contrast, with the Ac-P(2)-Pro(1) library, FAP cleaved only Ac-Gly-Pro, whereas DPP-4 showed little reactivity with all substrates. FAP also cleaved formyl-, benzyloxycarbonyl-, biotinyl-, and peptidyl-Gly-Pro substrates, which DPP-4 cleaved poorly, suggesting an N-acyl-Gly-Pro motif for inhibitor design. Therefore, we synthesized and tested the compound Ac-Gly-prolineboronic acid, which inhibited FAP with a K(i) of 23 +/- 3 nm. This was approximately 9- to approximately 5400-fold lower than the K(i) values for other prolyl peptidases, including DPP-4, DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase. These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl-Gly-Pro-based inhibitors will allow testing of FAP as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410248     DOI: 10.1074/jbc.M511112200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

Authors:  Aaron M LeBeau; W Nathaniel Brennen; Saurabh Aggarwal; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

4.  Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha.

Authors:  Jinbo Li; Kai Chen; Hongguang Liu; Kai Cheng; Meng Yang; Jiping Zhang; Jonathan D Cheng; Yan Zhang; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

6.  A sequence and structure based method to predict putative substrates, functions and regulatory networks of endo proteases.

Authors:  Prasanna Venkatraman; Satish Balakrishnan; Shashidhar Rao; Yogesh Hooda; Suyog Pol
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

7.  Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV.

Authors:  Koon Siew Lai; Nan-Hui Ho; Jonathan D Cheng; Ching-Hsuan Tung
Journal:  Bioconjug Chem       Date:  2007-05-10       Impact factor: 4.774

8.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

9.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

10.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.